SSR 128428 - sanofi-aventis
Alternative Names: SSR-128428; SSR128428ELatest Information Update: 04 Nov 2017
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antithrombotics; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis in Europe
- 11 Feb 2009 Phase-I clinical trials in Thrombosis in Europe (unspecified route)
- 12 Feb 2008 This programme is still in active development